Prescription patterns and clinical perspectives on intranasal corticosteroids in allergic rhinitis: insights from a nationwide survey of ENT specialists in India

Gayatri S. Pandit; Kunal Khobragade; Nitinkumar S.  Doshi

doi:10.18203/2394-6040.ijcmph20253265

Authors

Gayatri S. Pandit Samarth ENT and Allergy Centre, Bengaluru, Karnataka, India
Kunal Khobragade Department of Medical Affairs, Mankind Pharma Ltd., Navi Mumbai, Maharashtra,
Nitinkumar S. Doshi Department of Medical Affairs, Mankind Pharma Ltd., Navi Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20253265

Keywords:

Allergic rhinitis, ENT Specialists, Intranasal corticosteroids, Fluticasone furoate

Abstract

Background: Allergic rhinitis (AR) is an atopic disorder that presents with symptoms like nasal congestion, watery nasal discharge, sneezing, postnasal drip, and nasal itching. The worldwide prevalence of AR is about 10% to 25% and in children the prevalence rate is up to 40%. In India, around 20-30% of the population suffers from AR. The objective of this survey was to assess knowledge, attitude, and prescription patterns of intranasal corticosteroids (INCS) in the management of AR among ear-nose-throat (ENT) specialist in India.

Methods: A cross-sectional, real-world, in-clinic survey was conducted among 625 ENT specialists across India from August 2024 to October 2024. The respondents were administered a validated 30 questions survey.

Results: In the survey, 62.24% of ENT specialists consistently prescribe INCS for AR management, with 84.48% of them prefer fluticasone furoate. Most specialists (69.12%) prescribe INCS for a duration of 1 to 3 months, and 50.88% always use INCS for seasonal AR. Around 55.52% consider age as a key factor while prescribing INCS. For elderly patients 80.96% of the specialist preferred fluticasone furoate. Additionally, 89.12% believe INCS are the most effective AR treatment, and 76.00% routinely educate patients on proper nasal spray techniques.

Conclusions: The survey suggests that INCS are the top choice among ENT specialists for treating AR due to their efficacy and safety. Among the INCS, fluticasone furoate was the most preferred molecule. INCS play a key role in enhancing patients’ quality of life and delivering positive clinical outcomes.

Metrics

Metrics Loading ...

References

Kakli HA, Riley TD. Allergic rhinitis. Prim Care Clin Office Pract. 2016;43(3):465-75. DOI: https://doi.org/10.1016/j.pop.2016.04.009

Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allerg Clin Immunol. 2001;108(1):S2-8. DOI: https://doi.org/10.1067/mai.2001.115569

Varshney J, Varshney H. Allergic rhinitis: an overview. Indian J Otolaryngol Head Neck Surg. 2015;67(2):143-9. DOI: https://doi.org/10.1007/s12070-015-0828-5

Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D, Phase III Study Group TI. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allerg Immunol. 2008;19(2):110-24. DOI: https://doi.org/10.1111/j.1399-3038.2007.00601.x

Stempel DA, Woolf R. The cost of treating allergic rhinitis. Curr Allerg Asthma Rep. 2002;2(3):223-30. DOI: https://doi.org/10.1007/s11882-002-0023-0

Small P, Kim H. Allergic rhinitis. Allerg Asthma Clin Immunol. 2011;7(S1):S3. DOI: https://doi.org/10.1186/1710-1492-7-S1-S3

Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al. BSACI guideline for the diagnosis and management of allergic and non‐allergic rhinitis (revised edition 2017; 2007). Clin Exp Allerg. 2017;47(7):856-89. DOI: https://doi.org/10.1111/cea.12953

Shah A, Pawankar R. Allergic rhinitis and co-morbid asthma: perspective from India- ARIA Asia-Pacific Workshop report. Asian Pac J Allerg Immunol. 2009;27(1):71-7.

Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allerg. 2011;1(3):157-67. DOI: https://doi.org/10.5415/apallergy.2011.1.3.157

Giavina-Bianchi P. Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Ther Clin Risk Manag. 2008;4:465-72. DOI: https://doi.org/10.2147/TCRM.S1984

Chowdary Gaddipatti R, Rao SP, Rajiv K, Jain M. Isotonic nasal spray versus fluticasone nasal spray in treatment of allergic rhinitis. Int J Otorhinolaryngol Head Neck Surg. 2017;3(3):581. DOI: https://doi.org/10.18203/issn.2454-5929.ijohns20172007

Thorat S. Formulation and product development of nasal spray: an overview. Sch J Appl Med Sci. 2016;4(8D):2976-85.